Hair Loss Guide

How Finasteride Treats Male Hair Loss

Male pattern hair loss is one of the most studied conditions in dermatology. More than 50% of men experience it by age 50, and closer to 80% by age 70. For decades, the standard...

Male pattern hair loss is one of the most studied conditions in dermatology. More than 50% of men experience it by age 50, and closer to 80% by age 70. For decades, the standard of care has included finasteride, a drug that targets the hormonal mechanism behind follicle miniaturization.

What Is Male Pattern Hair Loss?

Male pattern hair loss, also called androgenetic alopecia, follows a characteristic path. Hair thins at the temples and crown, follicles shrink over time, and, eventually, some stop producing visible hair entirely.

The main driver is a hormone called dihydrotestosterone (or DHT). DHT is made from testosterone by an enzyme called 5-alpha reductase. In men with a genetic sensitivity to DHT, the hormone binds to receptors in the hair follicle and triggers a process called miniaturization.

The follicle produces thinner, shorter, lighter hair with each cycle. Over the years, it may stop producing hair at all.

DHT does not cause hair loss in every man. Instead, sensitivity is the key variable. Men with higher sensitivity to DHT experience loss at a faster rate and at a younger age.

Bottom line

Male pattern hair loss is driven by DHT acting on genetically sensitive follicles.

What Is Finasteride?

Finasteride is a 5-alpha reductase inhibitor, the enzyme that converts testosterone into DHT. It was first approved by the FDA in 1992 at 5 mg to treat benign prostatic hyperplasia. In 1997, the

FDA approved a 1 mg dose specifically for male pattern hair loss under the brand name Propecia.

By blocking the enzyme that converts testosterone into DHT, it lowers DHT levels in the blood.

Studies show it can lower DHT by around 70%. Oral finasteride also lowers DHT levels in the scalp.

That reduction in DHT is what allows follicles to recover. Follicles that are miniaturized may begin producing thicker, longer hair again.

Bottom line

Finasteride reduces DHT by about 70%. By reducing DHT effectively, it slows down, stops, and may even reverse the miniaturization.

What the Clinical Evidence Shows

The pivotal clinical trials for finasteride at 1 mg involved over 1,800 men with mild to moderate vertex hair loss. The trials ran for two years.

The results were consistent. In the placebo group, men lost hair throughout the two-year period.

In the finasteride group:

A five-year follow-up study found that these results held over time. Men who stayed on finasteride continued to maintain and in many cases improve their hair density. Men who stopped saw their DHT levels return to baseline within two weeks, and hair loss resumed within 12 months.

Scalp vertex (crown) responds more consistently than the hairline. Finasteride is less effective at restoring a receded front hairline than it is at maintaining and improving hair at the crown.

Bottom line

Finasteride works best when started early. Starting treatment at the first signs of thinning produces better outcomes than starting after significant loss.

Topical vs. Oral Finasteride

For decades, finasteride was available only as an oral pill. More recently, topical formulations have been developed that allow the drug to be applied directly to the scalp.

The case for topical finasteride centers around systemic exposure. While oral finasteride is absorbed into the bloodstream and reduces DHT throughout the body, topical finasteride is applied to the scalp. The goal is to deliver more of the active ingredient where it is needed, while lowering total body exposure.

A 2021 study published in the Journal of the American Academy of Dermatology found that 0.25% topical finasteride applied daily reduced scalp DHT by 70% while reducing serum DHT by only 20.2%.

This matters for men who want to limit exposure throughout the rest of the body. Topical delivery does not eliminate the drug from the bloodstream, but it meaningfully reduces systemic exposure while preserving most of the effectiveness at the scalp.

Bottom line

Topical finasteride delivers scalp DHT reduction comparable to the oral form with significantly lower systemic DHT suppression. It is a viable option for men who want to benefit from reduced systemic exposure.

How Long Does It Take to Work?

Finasteride does not produce quick results. The hair follicle cycle runs three to six months. Most men do not see visible improvement for six to twelve months.

The typical timeline looks like this:

Men who do not see results by 12 months are unlikely to be strong responders to finasteride alone. Combination with minoxidil or other agents may be considered.

Bottom line

Expect six to twelve months before visible improvement. Stopping early because results are slow is the most common reason treatment fails.

Side Effects and Risks

Finasteride has a well-documented risk profile. Mostly notably, men who use finasteride may experience sexual side effects: decreased libido, erectile dysfunction, and reduced ejaculate volume. Studies suggest this occurs in about 2% of men who use finasteride.

For the vast majority of men who experience these effects, they resolve when treatment stops.

A smaller subset of men report that sexual side effects persist after stopping treatment — a phenomenon sometimes called post-finasteride syndrome. The mechanism is debated and the research is ongoing.

Other reported side effects include breast tissue tenderness or enlargement (gynecomastia) in less than 1% of users.

Finasteride is not appropriate for women, particularly women who are pregnant or may become pregnant. The drug can cause birth defects in male fetuses if absorbed through the skin or ingested.

Bottom line

Sexual side effects affect a minority of users and often resolve with stopping treatment. Men with concerns should discuss their full history with a prescribing clinician before starting treatment.

Who Is a Good Candidate?

Finasteride is appropriate for adult men with androgenetic alopecia. It is most effective in men with:

Men with very advanced hair loss (Norwood VI or VII) have fewer viable follicles remaining and will see less benefit, though some stabilization is still possible.

Bottom line

The ideal candidate is a man in his 20s, 30s, or 40s who has noticed thinning within the past five years. Early intervention produces the best outcomes.

Combining Finasteride With Other Treatments

Finasteride addresses the hormonal driver of hair loss, blocking the signals that prevent follicles from functioning optimally. It does not necessarily stimulate follicle growth on its own. This is why combining it with minoxidil, which stimulates blood flow and follicle growth through a separate mechanism, has been shown to produce better results compared to either treatment alone.

A 2003 study found that the combination of oral finasteride and topical minoxidil was more effective than either agent alone at increasing hair count and visible hair density over a 12-month period.

Other adjuncts include low-level laser therapy, topical tretinoin (which enhances minoxidil absorption), and scalp health interventions that reduce inflammation and optimize the follicle environment.

Bottom line

Finasteride plus minoxidil is the most evidence-supported combination in hair loss treatment. Each addresses a different pathway — DHT suppression and follicle stimulation work together.

The Bottom Line

Finasteride is one of two FDA-approved medications for male pattern hair loss. It works by reducing DHT, the hormone responsible for follicle miniaturization, by about 70%. Clinical trials

show that the majority of men on finasteride maintain their hair density over two years, and many see meaningful regrowth. It is most effective when started early, requires consistent long-term use, and works best in combination with minoxidil. Side effects are real but affect a minority of users, and most resolve with stopping treatment.

References & Citations
  1. Kaufman, Keith D., et al. "Finasteride in the treatment of men with androgenetic alopecia." Journal of the American Academy of Dermatology, vol. 39, no. 4, 1998, pp. 578–589.
  2. Whiting, David A., et al. "Long-term efficacy and safety of finasteride 1 mg in male androgenetic alopecia." European Journal of Dermatology, vol. 13, no. 2, 2003, pp. 150–160.
  3. Piraccini, Bianca Maria, and Antonella Tosti. "Drug-related hair loss." Dermatologic Clinics, vol.
  4. 11, no. 3, 1993, pp. 543–551.
  5. Mysore, Venkataram. "Finasteride and sexual side effects." Indian Dermatology Online Journal, vol. 3, no. 1, 2012, pp. 62–65.
  6. Shapiro, Jerry, and Nina Otberg. Hair Loss: Principles of Diagnosis and Management of
  7. Alopecia. CRC Press, 2015.
  8. Rossi, A., et al. "Comparative effectiveness of finasteride vs serenoa repens in male androgenetic alopecia: a two-year study." International Journal of Immunopathology and
  9. Pharmacology, vol. 25, no. 4, 2012, pp. 1167–1173.
  10. Suchonwanit, Poonkiat, et al. "Minoxidil and its use in hair disorders: a review." Drug Design, Development and Therapy, vol. 13, 2019, pp. 2777–2786.